🛑 FDA cracks down on misleading oncology drug ads

The FDA has cited 22 drugmakersincluding AstraZeneca, Novartis, and BMSfor running "false or misleading" ads, targeting several cancer therapies.

Why It Matters To Oncology

▪ FDA flagged ads for Calquence (acalabrutinib), Truqap (capivasertib), Pluvicto (lutetium-177 vipivotide tetraxetan), and Kisqali (ribociclib) for overstating benefits or using distracting visuals.

▪ Ads implied enhanced quality of life or "transformative relief" unsupported by clinical data, raising concerns about patient expectations and informed consent.

The Financials

▪ Direct-to-consumer drug advertising is a multi-billion-dollar industryscrutiny could impact marketing strategies and drug uptake, especially for new oncology launches.

What They're Saying

▪ FDA called DTC ads a "pipeline of deception," with Commissioner Makary criticizing "distraction by design" tactics that downplay risks.

▪ Industry response pending as companies review the cease-and-desist letters and prepare adjustments.

What's Next

▪ FDA will require more explicit safety disclosures in ads and plans ongoing enforcement, potentially reshaping communication around oncology drugs and patient engagement.